Janux Therapeutics (JANX) Current Deferred Revenue: 2020-2024
Historic Current Deferred Revenue for Janux Therapeutics (JANX) over the last 3 years, with Jun 2024 value amounting to $94,000.
- Janux Therapeutics' Current Deferred Revenue fell 98.24% to $94,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $94,000, marking a year-over-year decrease of 98.24%. This contributed to the annual value of $1.7 million for FY2023, which is 68.46% down from last year.
- According to the latest figures from Q2 2024, Janux Therapeutics' Current Deferred Revenue is $94,000, which was down 90.33% from $972,000 recorded in Q1 2024.
- Janux Therapeutics' Current Deferred Revenue's 5-year high stood at $8.0 million during Q4 2020, with a 5-year trough of $94,000 in Q2 2024.
- In the last 3 years, Janux Therapeutics' Current Deferred Revenue had a median value of $4.8 million in 2022 and averaged $3.8 million.
- In the last 5 years, Janux Therapeutics' Current Deferred Revenue climbed by 12.20% in 2022 and then plummeted by 98.24% in 2024.
- Over the past 5 years, Janux Therapeutics' Current Deferred Revenue (Quarterly) stood at $8.0 million in 2020, then crashed by 35.46% to $5.2 million in 2021, then rose by 4.71% to $5.4 million in 2022, then plummeted by 68.46% to $1.7 million in 2023, then crashed by 98.24% to $94,000 in 2024.
- Its Current Deferred Revenue was $94,000 in Q2 2024, compared to $972,000 in Q1 2024 and $1.7 million in Q4 2023.